Ajinomoto Bio-Pharma Services presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective bioconjugation technology, AJICAP.    The AJICAP technology allows developers of therapeutic Antibody Drug Conjugates (ADCs) to better control both the location of payload conjugation to an antibody along with fine tuning the quantity of payload attached. Conventional ADCs which are currently commercially available are produced as heterogeneous mixtures con...